Vinícius Bonatto

Vinícius Bonatto

Auto-generated profile, based on publicly available information

Vinícius Bonatto

Medicinal and Biological Chemistry Group, São Carlos Institute of Chemistry, University of São Paulo, Avenue Trabalhador Sancarlense, 400, 13566-590, São Carlos/SP, Brazil

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2022 in RSC Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
VBVinícius Bonatto
Vinícius Bonatto
RLRafael F. Lameiro
Rafael F. Lameiro
FRFernanda R. Rocho
Fernanda R. Rocho
JLJeronimo Lameira
Jeronimo Lameira
ALAndrei Leitao
Andrei Leitao
CMCarlos A Montanari
Carlos A Montanari
This review highlights the roles of nitriles in covalent inhibitors, their reactivity, examples of pharmaceuticals containing the cyano group and recent developments of nitrile-based inhibitors.

16 January 2020 in Journal of Chemical Information and Modeling
Verified
Journal Article
Closed access
CCClauber H. S. da Costa
Clauber H. S. da Costa
VBVinícius Bonatto
Vinícius Bonatto
ASAlberto M. dos Santos
Alberto M. dos Santos
JLJeronimo Lameira
Jeronimo Lameira
ALAndrei Leitao
Andrei Leitao
CMCarlos A Montanari
Carlos A Montanari

10 March 2022 in Expert Opinion on Therapeutic Patents
Verified
Journal Article
Closed access
FRFernanda R. Rocho
Fernanda R. Rocho
VBVinícius Bonatto
Vinícius Bonatto
RLRafael F. Lameiro
Rafael F. Lameiro
JLJeronimo Lameira
Jeronimo Lameira
ALAndrei Leitao
Andrei Leitao
CMCarlos A Montanari
Carlos A Montanari
Cathepsin K (CatK) is a lysosomal cysteine protease and the predominant cathepsin expressed in osteoclasts, where it degrades the bone matrix. Hence, CatK is an attractive therapeutic target relate...

24 October 2019 in Physical Chemistry Chemical Physics
Verified
Journal Article
Closed access
PDF file
JLJeronimo Lameira
Jeronimo Lameira
VBVinícius Bonatto
Vinícius Bonatto
LCLorenzo Cianni
Lorenzo Cianni
FRFernanda dos Reis Rocho
Fernanda dos Reis Rocho
ALAndrei Leitao
Andrei Leitao
CMCarlos A Montanari
Carlos A Montanari
Nitrile reversible covalent inhibitors of human cathepsin L (hCatL) bind covalently to the side chain of the catalytic Cys25 residue in the S1 pocket to form thioimidates. Predicting the binding of reversible covalent inhibitors is essential for their practical application in drug design. In this report, five nitrile-based inhibitors coded Neq0570, Neq0710, Neq0802, Neq0803 and Neq0804 had their hCatL inhibition constants, Ki, determined. These analogs of the prototypical Neq0570 are halogenated reversible covalent inhibitors of hCatL, which bear a halogen atom in the meta position of the P3 benzyl ring that can form a halogen bond with the Gly61 of the hCatL. To describe halogen bonding interaction in an inhibitor-hCatL complex, we applied an extra point (EP) of charge to represent the anisotropic distribution of charge on the iodine, bromine and chlorine atoms. Besides, we have used alchemical free energy calculations for evaluating the overall relative binding free energies of these inhibitors using a two-state binding model: noncovalent and covalent bond states. Our results show that free energy perturbation (FEP) can predict the hCatL binding affinities of halogenated reversible covalent inhibitors in close agreement with experiments.

1 August 2020 in Bioorganic Chemistry
Verified
Journal Article
Closed access
LCLorenzo Cianni
Lorenzo Cianni
FRFernanda dos Reis Rocho
Fernanda dos Reis Rocho
FRFabiana Rosini
Fabiana Rosini
VBVinícius Bonatto
Vinícius Bonatto
JRJean F.R. Ribeiro
Jean F.R. Ribeiro
CMCarlos A Montanari
Carlos A Montanari

9 September 2020 in RSC Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
VBVinicius Bonatto
Vinicius Bonatto
PBPedro Henrique Jatai Batista
Pedro Henrique Jatai Batista
LCLorenzo Cianni
Lorenzo Cianni
DVDaniela De Vita
Daniela De Vita
DSDaniel G. Silva
Daniel G. Silva
CMCarlos A Montanari
Carlos A Montanari
The cysteine protease cruzipain is considered to be a validated target for therapeutic intervention in the treatment of Chagas disease. Hence, peptidomimetic cruzipain inhibitors having a reactive group (known as warhead) are subject to continuous studies to discover novel antichagasic compounds. Here, we evaluated how different warheads for a set of structurally similar related compounds could inhibit the activity of cruzipain and, ultimately, their trypanocidal effect. We first investigated in silico the intrinsic reactivity of these compounds by applying the Fukui index to correlate it with the enzymatic affinity. Then, we evaluated their potency against T. cruzi (Y and Tulahuen strains), which revealed the reversible cruzain inhibitor Neq0656 as a better trypanocidal agent (ECY.strain 50 = 0.1 μM; SI = 58.4) than the current drug benznidazole (ECY.strain 50 = 5.1 μM; SI > 19.6). We also measured the half-life time by HPLC analysis of three lead compounds in the presence of glutathione and cysteine to experimentally assess their intrinsic reactivity. Results clearly illustrated the reactivity trend for the warheads (azanitrile > aldehyde > nitrile), where the aldehyde displayed an intermediate intrinsic reactivity. Therefore, the aldehyde bearing peptidomimetic compounds should be subject for in-depth evaluation in the drug discovery process.